Analysis Tools
hematopoietic system
|
• mice have slightly lower platelet counts than controls (761.0 vs. 949.6)
|
|
• platelets aggregate less efficiently than controls to all tested agonists (thrombin, fibrinogen, ADP and the drug U46619)
• fibronigen binding is less than half that of controls
|
immune system
|
• TNF secretion is about 50% higher than controls in response to a lethal dose of LPS
|
|
• mice die faster than controls in response to LPS injections
• median survival time is 40 hours compared to 48 hours for controls
• all mutant mice die to the LPS injections compared to 80-85% of wild-type controls
• LPS injection leads to increased levels of TNF and D-dimers present in the serum
|
cardiovascular system
hemorrhage
(
J:150578
)
|
• mice have more bleeding as result of vascular damage that is secondary to inflammation
|
|
• LPS injections in the skin lead to lesions 4-fold larger than in controls, with nearly twice the degree of microscopic hemorrhage associated with Shwartzman lesions relative to controls
|
homeostasis/metabolism
|
• platelets aggregate less efficiently than controls to all tested agonists (thrombin, fibrinogen, ADP and the drug U46619)
• fibronigen binding is less than half that of controls
|
|
• LPS injection leads to increased levels of D-dimers present in the serum
|
|
• bleeding time is about double that of controls (87.33 seconds vs. 184.33 seconds)
|
integument
|
• LPS injections in the skin lead to lesions 4-fold larger than in controls, with nearly twice the degree of microscopic hemorrhage associated with Shwartzman lesions relative to controls
|
